The discussion follows questions councilors had during the last needle exchange workshop earlier this month about how to ...

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

If you're stocking up on Thanksgiving meal must-haves, this one can't be missed. Add it to your Amazon cart now.

Now imagine swapping some of that hardware for medicated skin cream that never pokes your skin. That is the vision behind a new Nature study describing a polymer that can haul insulin straight through ...

The Injector Collective is a revolutionary platform designed specifically for licensed injectors and medspa professionals. It ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...

A groundbreaking polymer-based skin cream shows promise in replacing painful daily insulin injections for diabetes management ...

III-directed small interfering ribonucleic acid designed to reduce levels of hepatic and serum apoC-III protein, thereby increasing clearance of serum TGs.

The MarketWatch News Department was not involved in the creation of this content.-- Omlyclo(TM) (omalizumab) is the first and only omalizumab biosimilar approved in Europe -- Omly ...